292 related articles for article (PubMed ID: 14965154)
1. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Hamid O
J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
[TBL] [Abstract][Full Text] [Related]
2. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
3. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
5. Cell signalling: growth factors and tyrosine kinase receptors.
Perona R
Clin Transl Oncol; 2006 Feb; 8(2):77-82. PubMed ID: 16632420
[TBL] [Abstract][Full Text] [Related]
6. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
8. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
9. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Grünwald V; Hidalgo M
J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
[TBL] [Abstract][Full Text] [Related]
10. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
11. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
Burris HA
Oncologist; 2004; 9 Suppl 3():10-5. PubMed ID: 15163842
[TBL] [Abstract][Full Text] [Related]
12. [Targeting epidermal growth factor receptor in cancer of the breast].
Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
[TBL] [Abstract][Full Text] [Related]
13. HER1/EGFR targeting: refining the strategy.
Pérez-Soler R
Oncologist; 2004; 9(1):58-67. PubMed ID: 14755015
[TBL] [Abstract][Full Text] [Related]
14. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
[TBL] [Abstract][Full Text] [Related]
15. Targeting the HER-kinase axis in cancer.
Gross ME; Shazer RL; Agus DB
Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
17. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
19. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]